Exlinkibart Biosimilar - Research Grade

Human

TNFRSF9

>1mg/ml

IgG1 - kappa

CHO Cells

Utomilumab Biosimilar - Research Grade (ICH5014), Urelumab Biosimilar - Research Grade (ICH5015), Evunzekibart Biosimilar - Research Grade (ICH5236)

https://www.imgt.org/mAb-DB/

ICH3002

Q07011

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of the anti-CD137 (4-1BB/TNFRSF9) agonist antibody Exlinkibart, supplied as a human IgG1-kappa built around the TNFRSF9 target for research use only. It reproduces the binding specificity of the originator molecule so investigators can study agonistic engagement of the 4-1BB co-stimulatory receptor without sourcing clinical material. Typical applications include use as a defined positive control in binding and receptor-engagement assays, a reference reagent when benchmarking in-house 4-1BB agonists or bispecifics, and a tool for dissecting co-stimulatory signaling in T-cell and NK-cell systems. It is offered at research grade with low endotoxin (<1 EU/mg; ultra-low <0.5 EU/mg options) and in bulk milligram-to-gram quantities suitable for assay development, in-vitro functional work, and preclinical characterization. It is not the clinical drug and is not intended for human or veterinary use. Content is provided for ichorbio to review and is educational, not a therapeutic claim. TNFRSF9, better known as 4-1BB or CD137 (UniProt Q07011), is a type I transmembrane member of the tumor necrosis factor receptor superfamily. It is an inducible co-stimulatory receptor expressed largely on activated CD8+ and CD4+ T cells, and also on NK cells, regulatory T cells, and dendritic cells. Its natural ligand is 4-1BBL (TNFSF9) presented on antigen-presenting cells. Ligand or agonist engagement triggers receptor clustering and recruitment of TRAF1 and TRAF2, driving NF-kB and MAPK (ERK, JNK, p38) signaling. Downstream effects include enhanced T-cell proliferation and survival, resistance to activation-induced cell death, increased cytokine production, memory CD8+ T-cell formation, and augmented cytotoxic and NK-mediated killing. These properties make 4-1BB a prominent co-stimulatory target for cancer immunotherapy and a widely studied node in T-cell activation biology.

4-1BB ligand receptor, CDw137, T-cell antigen 4-1BB homolog, T-cell antigen ILA, Tumor necrosis factor receptor superfamily member 9, CD137, ILA

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks